Azitra, Inc. is a preclinical stage biotechnology company harnessing the power of the microbiome to treat skin disease. The Company was founded in 2014 by scientists from Yale University and works with world-leading scientists in dermatology, microbiology, and genetic engineering to advance its programs in atopic dermatitis and targeted orphan indications. For more information visit www.azitrainc.com.
Azitra Inc的外部链接
21 Business Park Dr
US，Connecticut，Branford，06405
Azitra Inc转发了
Our team at Azitra is on fire lately! Last month, we announced the expansion of our patent portfolio and a $10 million financing. Earlier this week, we announced the screening of the first patient in our Phase 1b trial of ATR-12 for Netherton syndrome. And today, we're announcing the FDA has cleared our IND for a Phase 1/2 trial of ATR-04 for EGFR inhibitor-associated skin rash. Proud of our team! Now we're focused on execution and clinical data. https://lnkd.in/eivD4Tcj
Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome https://lnkd.in/eb2fzkQd
Azitra Inc转发了
Azitra Inc (NYSE American: AZTR) Announces Pricing of $10.0 Million Public Offering. Maxim Group LLC is acting as the exclusive placement agent. Read the full press release: https://lnkd.in/eiM4dhwu Brad Hoffman, Danny Fossey, Robert Solomon, Stephen Polsinelli
Today, we're announcing the strengthening of our IP portfolio with a newly issued US patent and three additional patent allowances globally. Read more here: https://lnkd.in/eNAB7rMF
We'll be at the Foundation for Foundation for Ichthyosis & Related Skin Types, Inc. (FIRST) conference this weekend to connect with patients and share about our clinical trial for Netherton syndrome at Azitra. #FIRSTNC24 #NethertonSyndrome
Azitra Inc转发了
This Friday, we'll be presenting new data on our platform and Netherton syndrome program at ASGCT 2024. Stop by if you'll be there! https://lnkd.in/e_j2riaH
This Friday, we'll be presenting new data on our platform and Netherton syndrome program at ASGCT 2024. Stop by if you'll be there! https://lnkd.in/e_j2riaH
Thrilled to announce new preclinical data from Azitra that we'll be presenting at ASGCT in a few weeks showing proof of concept of our platform and ATR-12 in Netherton syndrome models. Abstracts 281 and 318 here: https://lnkd.in/gwNTPdmP https://lnkd.in/guHUGFFe
Today, we’re announcing the issuance of a new patent to strengthen our IP position and bolster our platform for precision dermatology. https://lnkd.in/eMWwZqVn